Literature DB >> 15604615

Pharmacological treatment of acute renal failure in intensive care unit patients.

Delphine Moreau1.   

Abstract

Uric acid nephropathy is a potentially reversible cause of acute renal failure resulting from diffuse urate crystal depositions in the tubules in the setting of excessive uricosuria. Hyperuricemia is frequently encountered in ICU patients with acute renal failure of any etiology, but it is rarely a prominent feature or a major pathophysiological element in the renal failures of nonhematology/ oncology patients. It can, nevertheless, be severe in some pathologies associated with massive tissue destruction such as rhabdomyolysis. The most frequent clinical context is, nevertheless, hematological, when patients with large tumor burden and rapid cell turnover develop acute tumor lysis syndrome (ATLS). The purpose of this chapter is to review the pharmacological tools currently available and their optimal use in the treatment of patients admitted in intensive care unit with hyperuricemia and severe acute renal failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15604615     DOI: 10.1159/000082553

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  3 in total

Review 1.  Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

Authors:  Lisa Cammalleri; Mariano Malaguarnera
Journal:  Int J Med Sci       Date:  2007-03-02       Impact factor: 3.738

2.  Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report.

Authors:  Yohan Park; Byung Ha Chung; Cheol Whee Park; Yong-Soo Kim; Chul Woo Yang
Journal:  BMC Nephrol       Date:  2020-07-02       Impact factor: 2.388

3.  A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis.

Authors:  Sheik Oaleed Noordally; Schoeb Sohawon; Julien Vanderhulst; Ruth Duttmann; Francis Corazza; Jacques Devriendt
Journal:  Ann Saudi Med       Date:  2012 May-Jun       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.